When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ovarian carcinoma. Click to read.

an oral RAF/MEK clamp, in combination with defactinib. Under development at US pharma company Verastem Oncology (Nasdaq: VSTM ...

The FDA granted priority review to the company's avutometinib-defactinib application and expects to decide on approval in June 2025.

Shares of Verastem Oncology (VSTM) are up over 40% at $5.17 in premarket trading Tuesday, following a regulatory update. The ...

SpringWorks Therapeutics shows strong growth with approved drugs and potential for more, making it a promising buy. Read my ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Verastem Oncology announced that the FDA has accepted for review the New Drug Application, NDA, under the accelerated approval pathway for avutometinib, an ...

Lifileucel is under clinical development by Iovance Biotherapeutics and currently in Phase II for Endometrial Cancer.

INR:3631. cricket world cup list A medical representative advanced 200,000 yuan Revolution announces latest interim data on SHP2+MEK inhibitor The state is ...

NEJM: The risk of death is reduced by 31%. Darolutamide, a new drug for prostate cancer, improves survival Revolution announces latest interim data on SHP2+MEK inhibitor Correctly understand ...